Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection

Author affiliations

Abstract

Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319–541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.

Graphical abstract: Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection

Back to tab navigation

Supplementary files

Article information


Submitted
06 May 2020
Accepted
22 Jun 2020
First published
23 Jun 2020

Chem. Commun., 2020, Advance Article
Article type
Communication

Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection

X. Qi, B. Ke, Q. Feng, D. Yang, Q. Lian, Z. Li, L. Lu, C. Ke, Z. Liu and G. Liao, Chem. Commun., 2020, Advance Article , DOI: 10.1039/D0CC03263H

Social activity

Search articles by author

Spotlight

Advertisements